

## **Brazil launches an innovative program to develop the National Institutes for Science and Technology (INCTs): the INCT for Translational Medicine**

### **Brasil lança um programa inovador para desenvolver os Institutos Nacionais de Ciência e Tecnologia (INCTs): o INCT para Medicina Translacional**

The Brazilian System of Science and Technology has launched the National Institutes for Science and Technology which are intended as nation-wide networks of research. This initiative has been coordinated by the Ministry of Science and Technology and the *Conselho Nacional de Desenvolvimento Científico e Tecnológico* (CNPq); the Institutes were officially launched in November 2008. The budget for this initiative is about US\$260 million over the next five years. The Institutes will occupy a strategic position in the country and will be run in partnership with six State-run foundations for research support, in a joint effort with the Ministry of Health and Education, *Coordenação de Aperfeiçoamento de Pessoal de Nível Superior* (CAPES), Petrobras, and the National Bank for Social and Economic Development (BNDES).

The INCT for Translational Medicine represents perhaps a unique opportunity in the field of health-related research, since it offers a potential means of applying the findings obtained in basic research to everyday healthcare. The group awarded with the INCT-TM has become accustomed to the concept of translational research in its efforts to apply the advances made in the field of growth factors research to applications in psychiatry and neurology. In fact, the free enterprise sector has been faster than the Academia in using translational research to boost the development of products and patents. In this particular field, the Brazilian structure for research development is rather poor: while 2% of the science produced in the world comes from Brazil, only 0.1% of the total patents are filed by Brazilian researchers, a 20-fold gap. The INCT-TM has been designed to fill this gap within the area of health-related research. It was conceived as the collaborative effort of six centers: UFRGS, USP-RP, UFRJ, PUC-RS, UNESC and a core facility in which over 70 researchers and 150 students participate directly. The INCT-TM also has a wide interaction with several Brazilian and international research groups from different countries such as Canada, the UK, the USA and Spain.

Thus, we expect that the results of the ongoing and future studies of the INCT-TM will help Brazilian science to develop a translational edge, with greater attention paid to the potential benefits of using new findings from basic science as a means to achieve more effective healthcare.

**Flávio Kapczinski**

National Science and Technology Institute (INCT) for  
Translational Medicine  
Molecular Psychiatry Laboratory, Centro de Pesquisas,  
Hospital de Clínicas de Porto Alegre (HCPA),  
Universidade Federal do Rio Grande do Sul (UFRGS),  
Porto Alegre (RS), Brazil

**Jaime Eduardo Hallak**

National Science and Technology Institute (INCT) for  
Translational Medicine  
Neurosciences and Behavior Department,  
Faculdade de Medicina de Ribeirão Preto (FMRP),  
Universidade de São Paulo (USP),  
Ribeirão Preto (SP), Brazil

**Antonio Egidio Nardi**

National Science and Technology Institute (INCT) for  
Translational Medicine  
Laboratory of Panic and Respiration, Institute of Psychiatry,  
Universidade Federal do Rio de Janeiro (UFRJ),  
Rio de Janeiro (RJ), Brazil

**Rafael Roesler**

National Science and Technology Institute (INCT) for  
Translational Medicine  
Laboratory of Molecular Neuropharmacology,  
Department of Pharmacology, Instituto de Ciências Básicas  
da Saúde, Universidade Federal do Rio Grande  
do Sul (UFRGS), Porto Alegre (RS), Brazil  
Cancer Research Laboratory, Experimental Research  
Center, Hospital de Clínicas de Porto Alegre (HCPA),  
Porto Alegre (RS), Brazil

**João Quevedo**

National Science and Technology Institute (INCT) for  
Translational Medicine  
Laboratory of Neurosciences, Postgraduate Program in  
Health Sciences, Health Sciences Unit, Universidade do  
Extremo Sul Catarinense (UNESC), Criciúma (SC), Brazil

**Nadja Schröder**

National Science and Technology Institute (INCT) for  
Translational Medicine  
Neurobiology and Developmental Biology Laboratory,  
School of Biosciences, Pontifícia Universidade Católica do  
Rio Grande do Sul (PUC-RS), Porto Alegre (RS), Brazil

**José Alexandre S. Crippa**

National Science and Technology Institute (INCT)  
for Translational Medicine  
Neurosciences and Behavior Department,  
Faculdade de Medicina de Ribeirão Preto (FMRP),  
Universidade de São Paulo (USP-RP),  
Ribeirão Preto (SP), Brazil

## Disclosures

Writing group member	Employment	Research grant <sup>1</sup>	Other research grant or medical continuous education <sup>2</sup>	Speaker's honoraria	Ownership interest	Consultant/ Advisory board	Other <sup>3</sup>
Flávio Kapczinski	UFRGS	CNPq* CAPES* FIPE-HCPA* INCT-TM*	Astra-Zeneca* Stanley* NARSAD*	Lilly* Astra-Zeneca* Janssen* Servier*	-	Servier*	-
Jaime Eduardo Hallak	FMRP	FAPESP** CNPq** CAPES** FAEPA*	FAEPA*	-	-	-	-
Antonio Egidio Nardi	UFRJ	CNPq*	CNPq* Eurofarma*	Solvay* Hoffmann La-Roche*	-	CNPq* Hoffmann La-Roche*	Ed. Phoenix* Segmento Pharma* Ed. Elsevier* Eurofarma*
Rafael Roesler	UFRGS	CNPq FIPE/HCPA South American Officer for Anticancer Drug Development CAPES	-	-	Co-founder and partner NeuroAssay Research and Development Ltd	Eurofarma Laboratórios Instituto do Câncer Infantil do Rio Grande do Sul South American Officer for Anticancer Drug Development NeuroAssay Research and Development Ltd	-
João Quevedo	UNESC	-	-	-	-	-	-
Nadja Schröder	PUC-RS	CNPq CAPES	-	-	Co-founder and partner, NeuroAssay Research and Development Ltd	Co-founder and partner, NeuroAssay Research and Development Ltd	-
José Alexandre S. Crippa	FMRP	FAPESP** CNPq** CAPES** FAEPA*	FAEPA*	-	-	-	FUNPEC* Pfiser* Elli-Lilly* Astra-Zeneca*

\* Modest

\*\* Significant

\*\*\* Significant. Amounts given to the author's institution or to a colleague for research in which the author has participation, not directly to the author.

Note: HCPA = Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul; FMRP = Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo; UFRJ = Universidade Federal do Rio de Janeiro; UFRGS = Universidade Federal do Rio Grande do Sul; UNESC = Universidade do Extremo Sul Catarinense; PUC-RS = Pontifícia Universidade Católica do Rio Grande do Sul; CNPq = Conselho Nacional de Desenvolvimento Científico e Tecnológico; CAPES = Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; FIPE = Fundo de Incentivo à Pesquisa e Ensino; HCPA = Hospital de Clínicas de Porto Alegre; INCT-TM = Instituto Nacional de Ciência e Tecnologia Translacional em Medicina; FAPESP = Fundação de Amparo à Pesquisa do Estado de São Paulo; FAEPA = Fundação de Apoio ao Ensino, Pesquisa e Assistência do Hospital das Clínicas da FMRP-USP; FUNPEC = Fundação de Pesquisas Científicas.

For more information, see Instructions for authors.